Candel Therapeutics Inc

CADL remains in a Stage 2 advancing uptrend with aligned moving averages, but is trading near resistance and flagged as extremely overbought. Price is tightly tracking above the 9- and 20-day EMAs, lacking a clear short-term edge. Given the Speculative strategy, patience for a pullback into the 9- to 20-day EMA zone and subsequent acceptance on rising volume is preferred.

• ↑BLA submission for aglatimagene besadenovec on track, with Phase III data showing 39% improvement in disease-free survival.
• ↑Prostate cancer market potential estimated at $10–16 billion, driving significant revenue upside if approved.
• ↓Q2 2026 EPS loss of $0.52 missed by $0.30; net loss widened from $4.8 M to $38.9 M YoY.